Blood cancer patients in their 40s and 50s are urging Pharmac to overhaul its funding model, saying they have potentially ...

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the safety data from the phase 3 CEPHEUS trial in newly diagnosed multiple myeloma.

Daratumumab plus VRd and frontline daratumumab plus VTd produced deep, durable responses in patients with transplant-eligible multiple myeloma in updates to the PERSEUS and CASSIOPEIA trials ...

introduction导读伴单克隆免疫球蛋白沉积的增值性肾小球肾炎（PGNMID）是一种可以累及肾脏的病变。2004年Nasr提出，PGNMID应归为单克隆免疫球蛋白病（MGRS）。在这种疾病中，单克隆免疫球蛋白会沉积在肾小球中，从而引起补体激活、 ...

2024年欧洲肿瘤内科学会（ESMO）年会于近日在西班牙巴塞罗那盛大召开。作为肿瘤领域的国际顶级盛会之一，来自全球的专家学者齐聚一堂，共享前沿研究成果，共谋未来发展方向。在本次大会上，来自美国Albert Einstein医学院雅各比医学中心的Junmin Song教授，口头报告了首个BCMA CAR-T疗法与双特异性抗体治疗多发性骨髓瘤比较的真实世界研究结果（802MO），引发与会者的广泛关注。

Company AnnouncementNet sales of DARZALEX® in the third quarter of 2024 totaled USD 3,016 millionGenmab receives royalties on worldwide net sales ...

In the treatment of patients with newly diagnosed multiple myeloma (MM) who are not eligible for stem cell transplant or are transplant-deferred, adding subcutaneous daratumumab to bortezomib ...

A Christchurch family are considering uprooting their lives and moving to Australia to access the blood cancer drug their mum ...

Patients who received subcutaneous daratumumab plus bortezomib, lenalidomide, and dexamethasone (VRd) had better outcomes than patients who received VRd alone.

The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab for patients with newly diagnosed multiple myeloma. Patients newly ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...